Lexington, Massachusetts, January 25, 2023 /PRNewswire/ — Pulmatrix, Inc. (NASDAQ: PULM) is a clinical-stage biotechnology company developing a revolutionary inhaled therapy to address serious illness using its patented iSPERSE™ technology. The pharmaceutical company announced today that it will host a virtual Key Opinion Leader (KOL) event. , “PUR3100: Unlocking DHE Therapeutic Potential for the Treatment of Acute Migraine,” Special Issue Stewart J. TepperMD, of Geisel School of Medicine Dartmouth CollegeDr. Tepper describes the mechanism of action and clinical profile of dihydroergotamine (DHE) as well as the current state of treatment for migraine sufferers.Doctor Margaret Wasilewski Pulmatrix’s Chief Medical Officer, MD, then provided an update on the recently completed Phase 1 data for PUR3100, the company’s oral inhaled DHE, delivered using Pulmatrix’s iSPERSE™ technology, and future clinical trials. I will report on the plan.
the webinar is Friday, February 3, 2023 so 10:00 AM ET. A live Q&A session follows the formal presentation. Click here to register for the event.
Stewart J. TepperMD, is Professor of Neurology at the Geisel Medical School. Dartmouth College of Hanover, New HampshireHe is director of the Dartmouth Headache Center in the Department of Neurology at Dartmouth-Hitchcock Medical Center. Lebanon, New HampshireDr. Tepper holds a Bachelor of Arts degree with honors in Neuroscience/Psychobiology from Yale University. New Haven, Connecticutattend Cornell University medical college new york cityHe completed his neurology residency at the Longwood Area Harvard Program and Boston, Massachusettsand has been certified in Headache Medicine since 2006.
Dr. Tepper served as director of the American Headache Society’s Scottsdale Headache Symposium CME course from 2008-2020. He was the editor-in-chief of the journal. headache flow and associate editor of the journal headache From 2012 to 2020. He has published over 470 peer-reviewed manuscripts, editorials, and books on headache medicine. Dr. Tepper is a board member and corporate liaison for the American Headache Society. He serves on the AHS Education, Exhibits, and Finance Committee. He is also a member of the Migraine Foundation of America’s Governance Committee and Board of Directors.
About migraines
According to the Migraine Research Foundation, 38 million people in the United States experience migraine attacks, which are usually defined as one to two migraines per month. Migraine causes 1.2 million emergency room visits each year. Most people with migraine (75%) do not get complete relief from current prescription medications, indicating a need for new treatments. Limited and generally requires emergency department administration.
About Palmatrix
Pulmatrix is a clinical-stage biopharmaceutical company developing innovative inhaled therapies for severe pulmonary and non-pulmonary diseases using its patented iSPERSE™ technology. Our unique product pipeline includes the treatment of serious lung diseases, including PUR1900 for allergic bronchopulmonary aspergillosis (“ABPA”) and PUR1800 for chronic obstructive pulmonary disease (“COPD”). Our pipeline also includes his PUR3100 for neurological disorders such as acute migraine, where rapid systemic exposure may be beneficial. Pulmatrix’s product candidates are based on iSPERSE™, a uniquely designed dry powder delivery platform.
About iSPERSE™ Technology
Our innovative particle engineering technology overcomes the limitations of traditional inhalation technology to create dry powders that expand the world of inhaled drug therapy. iSPERSE is a proprietary technology that allows a broad spectrum of drugs to be formulated as small, dense, dispersible particles for highly efficient drug delivery and deep lung penetration. iSPERSE can efficiently deliver small molecules, drug combinations, peptides, proteins, and nucleic acids through the respiratory system for the treatment of both respiratory and non-respiratory diseases.
Forward-Looking Statements
Certain forward-looking statements in this letter, which are not statements of historical fact, are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. is a statement of historical fact, “predict”, “assume”, “believe”, “could”, “could”, “estimate”, “expect”, “extended” , may be identified by words such as “predict”. “Guide”, “Intend”, “Believe”, “Could”, “Plan”, “Seek”, “Project”, “Goal”, and “Will” , and their antonyms and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are based on management’s beliefs and assumptions made by management and information currently available. Actual results are anticipated in forward-looking statements as a result of certain factors, including, but not limited to, the impact of COVID-19 on our ongoing and planned clinical trials. may differ significantly from The geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future as needed. delays in planned clinical trials; the ability to demonstrate that a potential product is efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations regarding the development of therapeutic candidates. Ability to obtain appropriate or necessary governmental approvals to market potential products. the ability to obtain future funding for development products and working capital, and the ability to obtain such funding on commercially reasonable terms; our ability to manufacture product candidates on a commercial scale or in collaboration with third parties; Changes in the size and nature of our competitors. Ability to retain key executives and scientists. Ability to secure and enforce legal rights related to our products, including patent protection. A discussion of these and other factors, including the risks and uncertainties regarding the Company, is contained in the Company’s filings with the SEC, including its most recent annual report on Form 10-K. Quarterly Report on Form 10-Q. We disclaim any intention or obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Investor Contact:
Timothy McCarthyCFA
917-679-9282
tim@lifesciaadvisors.com
To download multimedia, please view the original content. -dhe-cure potential-301729996.html
Sauce Parmatrix
